Educational guide
Oral peptide delivery Systems: Synergistic approaches ...
Published by: Elsevier Published by Review article Open access Under a Creative Commons license Article Highlights • Oral peptide delivery faces stability and permeability challenges. • Lipid and polymer-based carriers enhance peptide absorption. • Needle-base
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Published by: Elsevier
Published by
Review article
Open access
Under a Creative Commons license
Highlights
- •
Oral peptide delivery faces stability and permeability challenges.
- •
Lipid and polymer-based carriers enhance peptide absorption.
- •
Needle-based systems like LUMI and SOMA improve insulin delivery.
- •
Tablets like Eligen and ORLADEL offer innovative peptide formulations.
Abstract
Oral peptide delivery remains a significant challenge due to physiological barriers, enzymatic degradation, and limited permeability in the gastrointestinal tract (GIT). The harsh conditions of the GIT, including enzymatic hydrolysis and pH variations, contribute to the instability of peptides, leading to poor bioavailability. To overcome these challenges, advanced drug delivery systems have been developed, incorporating various strategies to enhance peptide absorption. These include polymer-based carriers that can enhance mucoadhesion or mucodiffusion, bacteria-based systems that facilitate binding, and a range of nanoparticle systems—such as lipid- and polymer-based carriers—that protect peptides from enzymatic degradation. Additionally, chemical and structural modifications, as well as targeting ligands, have been explored to enhance stability and absorption. Recent innovations in oral peptide drug delivery include novel formulations such as Eligen and ORLADEL oral tablets, insulin bubble carriers, and intestinal patches. The use of mesoporous carriers has also gained attention for their ability to improve peptide stability and permeability. Furthermore, swallowable needle-based systems such as LUMI and SOMA have been developed to facilitate insulin delivery. These advancements represent promising solutions for improving oral peptide bioavailability, yet further research is needed to refine these technologies and ensure their safety, scalability, and efficacy in clinical applications.
Keywords
Peptide
;
Oral delivery
;
Insulin
;
Lipids
;
LUMI
;
SOMA
Data availability
No data was used for the research described in the article.
Recommended articles
No articles found.
© 2025 The Authors. Published by Elsevier B.V.